Subjective response to alcohol

Last updated

Subjective response to alcohol (SR) refers to an individual's unique experience of the pharmacological effects of alcohol and is a putative risk factor for the development of alcoholism. Subjective effects include both stimulating experiences typically occurring during the beginning of a drinking episode as breath alcohol content (BAC) rises and sedative effects, which are more prevalent later in a drinking episode as BAC wanes. [1] The combined influence of hedonic and aversive subjective experiences over the course of a drinking session are strong predictors of alcohol consumption and drinking consequences. [2] There is also mounting evidence for consideration of SR as an endophenotype with some studies suggesting that it accounts for a significant proportion of genetic risk for the development of alcohol use disorder. [2] [3]

Contents

Theoretical models

Low Level of Response Model

The Low Level of Response Model proposes that individuals who are less sensitive to the effects of alcohol are at greater risk for developing alcohol use disorder. One explanation for this phenomenon is that the experiences of elevated intoxication constitutes a feedback mechanism, which prompts drinking cessation. Low-level responders need to consume more alcohol than high responders to achieve a similar level of intoxication and experience the aversive effects of alcohol; consequently, these individuals must consume more alcohol to trigger the negative feedback loop. [3] [4] Escalating alcohol consumption may ultimately contribute to the development of tolerance, which further dampens sensitivity to alcohol's unpleasant effects. Notably, there is no population-level demarcation separating low from high responders and so level of response is arbitrarily defined (generally in terciles) within a given sample. [3]

Early studies compared SR in individuals (mostly males) with (FH+) and without (FH-) a family history of alcohol dependence in order to demonstrate that individual differences in SR could be considered genetically linked determinants of alcohol use disorder. Non-placebo controlled studies conducted by Schuckit and colleagues found that FH+ males experienced less of the aversive effects of alcohol as compared to FH- males matched on key demographic and body mass variables. [3] Furthermore, FH+ young males and their fathers showed similar SR after reaching peak BAC, suggesting that SR is a heritable risk factor for the development of alcohol use disorder. [3] Schuckit's placebo-controlled studies generally reported lower SR among FH+, as compared to FH-, subjects along declining BAC, with differences more evident among men than women. Additional studies found that FH+ subjects who experienced low-level of response were more than 4 times as likely to meet criteria for alcohol use disorder at 10-year follow-up as compared to FH- subjects who reported the same SR pattern. [5] Subsequent follow-up studies conducted primarily by Schuckit's group established that low-level of response is a genetically linked risk factor for alcohol use disorder, which is not better explained by robust confounding factors such as age of first drink, current alcohol use and impulsivity. [3] [6] A 1992 meta-analysis further buttressed the Low Level of Response Model by reporting that sons of alcoholics exhibited lower responses to alcohol on both the ascending and descending limbs of the BAC curve. Importantly, differences in SR by family history were significant only in the alcohol condition and not the placebo condition, suggesting that SRs observed in the alcohol condition could be attributed to the pharmacological effects of alcohol, rather than to a confounding factor. [5] A 2011 meta-analysis revealed that FH+ individuals reported lower SR in comparison to FH- individuals across both limbs of intoxication, consistent with the Low Level of Response Model. [4] These findings were more robust along the descending limb of the BAC curve where sedative effects of alcohol are more prevalent and among males who comprised the overwhelming majority of participants in early SR studies.

Critics noted that studies supporting the Low Level of Response Model only accounted for the negatively valenced sedative effects of alcohol and that while decreased sensitivity to aversive effects of alcohol would likely lead to increased drinking frequency and severity, the subjective effects of alcohol are, in actuality, quite varied. [3] For example, it is widely accepted that the rewarding properties of alcohol are reinforcing. Yet, according to the Low Level of Response Model, reduced sensitivity to these rewarding effects is an indicator of problematic drinking. To that end, critics have noted that in Schuckit's seminal SR study, [7] FH+ males experienced more "energy" than FH- males along rising BAC, suggesting that heightened sensitivity to the stimulating effects of alcohol may convey risk for developing alcohol problems. [3] Another study found that FH+ subjects reported experiencing less intoxication than FH- subjects in response to a placebo drink, indicating that alcohol expectancies may account for differences in risk more so than SR. [8] That is, individuals at greatest risk for developing alcohol use disorder may expect alcohol to be more enjoyable and less aversive than low-risk individuals.

Differentiator Model

The Differentiator Model [9] is based on the widely accepted notion that alcohol's effects are biphasic. That is, the stimulating effects of alcohol (i.e., euphoria, sociality, energy) are more prevalent as BAC rises (i.e., ascending limb), while alcohol's sedative effects (i.e., relaxation, nausea, headaches) are experienced most strongly as BAC falls (i.e., descending limb). The Differentiator Model proposes that individuals at greatest risk for developing alcohol use disorder (or those who already meet criteria for alcohol use disorder) are more sensitive to the stimulating effects of alcohol on the ascending limb of intoxication and less sensitive to the sedative effects on the descending limb. [3] [4] Additionally, the combination of heightened rewards and diminished consequences over the course of a drinking episode increases motivation to consume alcohol, leading to longer and more frequent drinking episodes. Repeated engagement in these risky drinking occasions may ultimately contribute to the development of alcohol use disorder.

Support for the Differentiator Model is mixed, perhaps reflecting the paucity of studies designed to test the model itself or record SR over both limbs of intoxication. [2] [3] Both oral and intravenous alcohol administration studies reported that FH+ subjects experienced elevated sensitivity to stimulating effects of alcohol along rising BAC, without the corresponding attenuation of sedative effects as BAC fell. [3] A study using an intravenous alcohol clamping method (participants were titrated to a BAC of .06 g/dl whereupon alcohol was infused to maintain a stable BAC for the duration of the study) reported that FH+ subjects experienced heightened stimulation on the ascending limb of intoxication, consistent with the Differentiator Model. [10] However, FH+ subjects reported decreased stimulation during clamping, indicative of acute tolerance.

Findings by King and colleagues, which are largely corroborated by a recent meta-analysis, suggest that the Differentiator Model best characterizes heavy drinkers at risk for developing alcohol use disorder. [2] [4] Specifically, over the course of several studies, heavy drinkers reported greater positive SR on the ascending limb of intoxication and lower negative SR on the descending limb, in relation to light drinkers. [11] Increased sensitivity to alcohol's stimulating effects along rising BAC and muted sensitivity to alcohol's sedative effects along waning BAC were subsequently predictive of future increases in binge drinking, blackouts, hangovers and alcohol use disorder symptomatology. [2] [12] [13]

Measurement

The Subjective High Assessment Scale (SHAS) captures sensations frequently associated with intoxication such as "clumsy," "dizzy," "drunk" and "high" and was administered extensively in early SR studies. [14] The SHAS is typically administered as a visual analog scale, allowing subjects to rate the extent to which they experienced each symptom during a given experiment. [15] Critics of the measure argue that it primarily captures the sedative effects of alcohol while omitting many of alcohol's stimulating properties. [3] The Biphasic Effects of Alcohol Scale (BAES) assesses 7 stimulating (elated, energized, excited stimulated, talkative, up, vigorous) and 7 sedative (difficulty concentrating, down, heavy head, inactive, sedated, slow thoughts, sluggish) effects of alcohol along an 11-point scale. [1] Studies supporting the Differentiator Model have almost universally used the BAES, rather than the SHAS, as a measure of SR. [4] Critics of the BAES assert that it does not adequately capture positive sedative effects. [3] The Subjective Effects of Alcohol Scale (SEAS) [16] was published in 2013 to address this apparent limitation by referencing positive and negative stimulating and sedative effects; to date, this scale has not been widely used in alcohol challenge studies.

Genetic moderators

Most genetic studies in addiction research focus on the genetic determinants of diagnostic phenotypes such as alcohol use disorder. However, because the causes of alcohol use disorder are so numerous and varied, researchers have turned their attention to endophenotypes, or distinct, genetically linked phenotypes associated with a broad disorder. Endophenotypes are especially useful in addictions research because they are more closely linked to genetic variations than the broad disorder. Therefore, investigators have explored the effects of genetic variation in the endogenous opioid system and the GABAergic system on SR. [2]

Alcohol activates endogenous opioid receptors, potentiating dopamine release which increases the rewarding effects of alcohol. To that end, the A118G single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1), has garnered much interest as a potential moderator of SR. [17] Numerous laboratory studies have demonstrated that G-allele carriers experience the stimulating, hedonic effects of alcohol more strongly than A homozygotes. [18] However, a study of non-treatment seeking participants with alcohol dependence found that A homozygotes experienced more stimulation than G carriers, and a study of heavy drinkers reported no differences in SR between OPRM1 genotype. These mixed findings may stem from differences in alcohol use severity among samples, as the allostatic model of addiction contends that individuals shift from reward to relief drinking as alcohol use disorder progresses. [19] Thus, it is possible that social drinkers and individuals with mild alcohol use disorder may experience the hedonic effects of alcohol as most salient while individuals with more severe alcohol use disorder may consume alcohol for its negative reinforcing properties (i.e., to reduce withdrawal symptoms). The use of retrospective, instead of real time, self-reports of SR as well as differences in ethnicities of samples may further contribute to discrepancies in studies exploring the effects of the OPRM1 gene and SR. Taken together, the literature pertaining to the expression of SR by OPRM1 genotype suggests that the A118G SNP of the OPRM1 gene is associated with enhanced sensitivity to the stimulating, but not sedative, effects of alcohol. [2]

Expression of the DAT1 dopamine transporter gene has also been shown to predict severity of alcohol use disorder symptoms with a recent study linking simultaneous carriers of the OPRM1 G-allele and DAT1 A10 allele homozygotes to pleasurable subjective effects along rising BAC. [2] [18]

Alcohol researchers have also evaluated the role of gamma-Aminobutyric acid (GABA) receptors as moderators of SR. Most investigation has focused on genes coding for GABAA receptors, which are involved in dopamine release. Some studies have linked GABRA2 and GABRG1 genes to reductions in the experience of positive and negative subjective effects. [2] [18]

Clinical implications

Because SR is such a strong predictor of future alcohol consumption and problems, medication development has focused on drugs which either reduce the pleasant or increase the unpleasant effects of alcohol.

Naltrexone, an opioid receptor antagonist, is frequently prescribed to patients suffering from alcohol use disorder, with moderate effectiveness. [20] Studies have demonstrated that naltrexone reduces the stimulating and heightens the aversive sedative effects of alcohol in individuals at-risk for alcohol use disorder, contributing to decreases in self-reported subjective high and liking of alcohol. [21] [22] [23] Only one study has reported on the effects of naltrexone on SR in a sample of participants with alcohol dependence: naltrexone, in comparison to a placebo, attenuated subjective stimulation within 10 minutes of administration of a moderate dose of alcohol, but not thereafter. [24]

Laboratory studies have shown that OPRM1 genotype moderates the subjective effects of naltrexone in social and heavy drinkers, such that G carriers reported reduced sensitivity to the stimulating effects of alcohol. [2] Moreover, a placebo-controlled study of heavy drinkers of East Asian descent demonstrated that G carriers experienced greater sensitivity to alcohol's aversive effects as compared to A homozygotes. [2]

There is limited evidence suggesting that quetiapine and varenicline increase the aversive effects of alcohol. [2]

Related Research Articles

<span class="mw-page-title-main">Alcoholism</span> Problematic excessive alcohol consumption

Alcoholism is the continued drinking of alcohol despite negative results. Problematic use of alcohol has been mentioned in the earliest historical records, such as in ancient Egypt and in the Bible, and remains widespread; the World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide as of 2016. The term alcoholism was first coined in 1852, but alcoholism and alcoholic are stigmatizing and discourage seeking treatment, so clinical diagnostic terms such as alcohol use disorder or alcohol dependence are used instead.

<span class="mw-page-title-main">Alcohol abuse</span> Misuse of alcoholic beverages resulting in negative consequences

Alcohol abuse encompasses a spectrum of unhealthy drinking behaviors which range from consuming more than 2 drinks per day on average for men, or more than 1 drink per day on average for women, to binge drinking or alcohol use disorder.

The health effects of long-term alcohol consumption on health vary depending on the amount of ethanol consumed. Even light drinking poses health risks, but small amounts of alcohol may also have health benefits. Chronic heavy drinking causes severe health consequences which outweigh any potential benefits.

<span class="mw-page-title-main">Naltrexone</span> Medication

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken by mouth or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur. Side effects may include trouble sleeping, anxiety, nausea, and headaches. In those still on opioids, opioid withdrawal may occur. Use is not recommended in people with liver failure. It is unclear if use is safe during pregnancy. Naltrexone is an opioid antagonist and works by blocking the effects of opioids, including both opioid drugs as well as opioids naturally produced in the brain.

<span class="mw-page-title-main">Alcohol tolerance</span> Bodily responses to the functional effects of ethanol in alcoholic beverages

Alcohol tolerance refers to the bodily responses to the functional effects of ethanol in alcoholic beverages. This includes direct tolerance, speed of recovery from insobriety and resistance to the development of alcohol use disorder.

<span class="mw-page-title-main">Acamprosate</span> Medication

Acamprosate, sold under the brand name Campral, is a medication used along with counseling to treat alcohol use disorder.

The Alcohol Use Disorders Identification Test (AUDIT) is a ten-item questionnaire approved by the World Health Organization to screen patients for hazardous (risky) and harmful alcohol consumption. It was developed from a WHO multi-country collaborative study, the items being selected for the AUDIT being the best performing of approximately 150 items including in the original survey. It is widely used as a summary measure of alcohol use and related problems. It has application in primary health care, medical clinics, and hospital units and performs well in these settings. Using different cut-off points, it can also screen for Alcohol Use Disorder (DSM-5) and Alcohol Dependence. Guidelines for the use of the AUDIT have been published by WHO and are available in several languages. It has become a widely used instrument and has been translated into approximately fifty languages.

The modern disease theory of alcoholism states that problem drinking is sometimes caused by a disease of the brain, characterized by altered brain structure and function.

A drug-related blackout is a phenomenon caused by the intake of any substance or medication in which short-term and long-term memory creation is impaired, therefore causing a complete inability to recall the past. Blackouts are frequently described as having effects similar to that of anterograde amnesia, in which the subject cannot recall any events after the event that caused amnesia.

<span class="mw-page-title-main">Hangover</span> Discomfort following alcohol consumption

A hangover is the experience of various unpleasant physiological and psychological effects usually following the consumption of alcohol, such as wine, beer, and liquor. Hangovers can last for several hours or for more than 24 hours. Typical symptoms of a hangover may include headache, drowsiness, concentration problems, dry mouth, dizziness, fatigue, gastrointestinal distress, absence of hunger, light sensitivity, depression, sweating, hyper-excitability, irritability, and anxiety.

<span class="mw-page-title-main">QH-II-66</span> Sedative drug

QH-II-66 (QH-ii-066) is a sedative drug which is a benzodiazepine derivative. It produces some of the same effects as other benzodiazepines, but is much more selective than most other drugs of this class and so produces somewhat less sedation and ataxia than other related drugs such as diazepam and triazolam, although it still retains anticonvulsant effects.

Alcohol myopia is a cognitive-physiological theory on alcohol use disorder in which many of alcohol's social and stress-reducing effects, which may underlie its addictive capacity, are explained as a consequence of alcohol's narrowing of perceptual and cognitive functioning. The alcohol myopia model posits that rather than disinhibit, alcohol produces a myopia effect that causes users to pay more attention to salient environmental cues and less attention to less salient cues. Therefore, alcohol's myopic effects cause intoxicated people to respond almost exclusively to their immediate environment. This "nearsightedness" limits their ability to consider future consequences of their actions as well as regulate their reactive impulses.

The impact of alcohol on aging is multifaceted. Evidence shows that alcoholism or chronic alcohol consumption can cause both accelerated (or premature) aging – in which symptoms of aging appear earlier than normal – and exaggerated aging, in which the symptoms appear at the appropriate time but in a more exaggerated form. The effects of alcohol use disorder on the aging process include hypertension, cardiac dysrhythmia, cancers, gastrointestinal disorders, neurocognitive deficits, bone loss, and emotional disturbances especially depression. On the other hand, research also shows that drinking moderate amounts of alcohol may protect healthy adults from developing coronary heart disease. The American Heart Association cautions people not to start drinking, if you are not already drinking.

<span class="mw-page-title-main">Alcohol withdrawal syndrome</span> Symptoms that can occur following a reduction in alcohol use after a period of excessive use

Alcohol withdrawal syndrome (AWS) is a set of symptoms that can occur following a reduction in alcohol use after a period of excessive use. Symptoms typically include anxiety, shakiness, sweating, vomiting, fast heart rate, and a mild fever. More severe symptoms may include seizures, and delirium tremens (DTs) which can be fatal in untreated patients. Symptoms start at around 6 hours after last drink. Peak incidence of seizures occurs at 24-36 hours and peak incidence of delirium tremens is at 48-72 hours.

<span class="mw-page-title-main">Short-term effects of alcohol consumption</span> Overview of the short-term effects of the consumption of alcoholic beverages

The short-term effects of alcohol consumption range from a decrease in anxiety and motor skills and euphoria at lower doses to intoxication (drunkenness), to stupor, unconsciousness, anterograde amnesia, and central nervous system depression at higher doses. Cell membranes are highly permeable to alcohol, so once it is in the bloodstream, it can diffuse into nearly every cell in the body.

<span class="mw-page-title-main">Binge drinking</span> Form of excessive alcohol intake

Binge drinking, or heavy episodic drinking, is drinking alcoholic beverages with an intention of becoming intoxicated by heavy consumption of alcohol over a short period of time, but definitions vary considerably.

Alcohol and sex deals with the effects of the consumption of alcohol on sexual behavior. The effects of alcohol are balanced between its suppressive effects on sexual physiology, which will decrease sexual activity, and its suppression of psychological inhibitions, which may increase the desire for sex.

<span class="mw-page-title-main">Effects of alcohol on memory</span> Health effect of alcohol consumption

Ethanol is the type of alcohol found in alcoholic beverages. It is a volatile, flammable, colorless liquid that acts as a central nervous system depressant. Ethanol can impair different types of memory.

Kindling due to substance withdrawal is the neurological condition which results from repeated withdrawal episodes from sedative–hypnotic drugs such as alcohol and benzodiazepines.

<span class="mw-page-title-main">Alcohol (drug)</span> Active ingredient in alcoholic beverages

Alcohol, sometimes referred to by the chemical name ethanol, is a depressant drug that is the active ingredient in fermented drinks such as beer, wine, and distilled spirits. It is one of the oldest and most commonly consumed recreational drugs, causing the characteristic effects of alcohol intoxication ("drunkenness"). Among other effects, alcohol produces happiness and euphoria, decreased anxiety, increased sociability, sedation, impairment of cognitive, memory, motor, and sensory function, and generalized depression of central nervous system (CNS) function.

References

  1. 1 2 Martin, Christopher S.; Earleywine, Mitchell; Musty, Richard E.; Perrine, M. W.; Swift, Robert M. (1 February 1993). "Development and Validation of the Biphasic Alcohol Effects Scale". Alcoholism: Clinical and Experimental Research. 17 (1): 140–146. doi:10.1111/j.1530-0277.1993.tb00739.x. ISSN   1530-0277. PMID   8452195.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 Roche, Daniel JO; Ray, Lara A (1 May 2015). "Subjective response as a consideration in the pharmacogenetics of alcoholism treatment". Pharmacogenomics. 16 (7): 721–736. doi:10.2217/pgs.14.143. ISSN   1462-2416. PMID   25950242. S2CID   7828383.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 Morean, Meghan E.; Corbin, William R.; Treat, Teresa A. (December 2015). "Evaluating the accuracy of alcohol expectancies relative to subjective response to alcohol". Addictive Behaviors. 51: 197–203. doi:10.1016/j.addbeh.2015.07.027. PMC   4772766 . PMID   26291291.
  4. 1 2 3 4 5 Quinn, P; Fromme, K (October 2011). "Subjective response to alcohol challenge: a quantitative review". Alcoholism: Clinical and Experimental Research. 35 (10): 1759–70. doi:10.1111/j.1530-0277.2011.01521.x. PMC   3183255 . PMID   21777258.
  5. 1 2 Pollock, VE (1 November 1992). "Meta-analysis of subjective sensitivity to alcohol in sons of alcoholics". American Journal of Psychiatry. 149 (11): 1534–1538. doi:10.1176/ajp.149.11.1534. ISSN   0002-953X. PMID   1415821.
  6. ↑ Trim, Ryan S.; Schuckit, Marc A.; Smith, Tom L. (1 September 2009). "The Relationships of the Level of Response to Alcohol and Additional Characteristics to Alcohol Use Disorders Across Adulthood: A Discrete-Time Survival Analysis". Alcoholism: Clinical and Experimental Research. 33 (9): 1562–1570. doi:10.1111/j.1530-0277.2009.00984.x. ISSN   1530-0277. PMC   2947374 . PMID   19485971.
  7. ↑ "Self-rating of alcohol intoxication by young men with and without family histories of alcoholism". Journal of Studies on Alcohol. 41.
  8. ↑ O'Malley, S S; Maisto, S A (4 January 2015). "Effects of family drinking history and expectancies on responses to alcohol in men". Journal of Studies on Alcohol. 46 (4): 289–297. doi:10.15288/jsa.1985.46.289. PMID   4033129.
  9. ↑ Newlin, David B.; Thomson, James B. (1990). "Alcohol challenge with sons of alcoholics: A critical review and analysis". Psychological Bulletin. 108 (3): 383–402. doi:10.1037/0033-2909.108.3.383. PMID   2270234.
  10. ↑ Morzorati, S. L.; Ramchandani, V. A.; Flury, L.; Li, T.-K.; O'Connor, S. (1 August 2002). "Self-Reported Subjective Perception of Intoxication Reflects Family History of Alcoholism When Breath Alcohol Levels Are Constant". Alcoholism: Clinical and Experimental Research. 26 (8): 1299–1306. doi:10.1111/j.1530-0277.2002.tb02670.x. ISSN   1530-0277. PMID   12198408.
  11. ↑ King, Andrea C.; Wit, Harriet de; McNamara, Patrick J.; Cao, Dingcai (4 April 2011). "Rewarding, Stimulant, and Sedative Alcohol Responses and Relationship to Future Binge Drinking". Archives of General Psychiatry. 68 (4): 389–99. doi:10.1001/archgenpsychiatry.2011.26. ISSN   0003-990X. PMC   4633413 . PMID   21464363.
  12. ↑ King, Andrea C.; McNamara, Patrick J.; Hasin, Deborah S.; Cao, Dingcai (15 May 2014). "Alcohol Challenge Responses Predict Future Alcohol Use Disorder Symptoms: A 6-Year Prospective Study". Biological Psychiatry. 75 (10): 798–806. doi:10.1016/j.biopsych.2013.08.001. PMC   4280017 . PMID   24094754.
  13. ↑ King, Andrea C.; Hasin, Deborah; O'Connor, Sean J.; McNamara, Patrick J.; Cao, Dingcai (15 March 2016). "A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder". Biological Psychiatry. 79 (6): 489–498. doi:10.1016/j.biopsych.2015.05.007. PMC   4644521 . PMID   26117308.
  14. ↑ Judd, Lewis L. (1 April 1977). "Lithium Carbonate and Ethanol Induced "Highs" in Normal Subjects". Archives of General Psychiatry. 34 (4): 463–7. doi:10.1001/archpsyc.1977.01770160097008. ISSN   0003-990X. PMID   322635.
  15. ↑ Schuckit, Marc A. (1 March 1988). "A Simultaneous Evaluation of Multiple Markers of Ethanol/Placebo Challenges in Sons of Alcoholics and Controls". Archives of General Psychiatry. 45 (3): 211–6. doi:10.1001/archpsyc.1988.01800270019002. ISSN   0003-990X. PMID   3422553.
  16. ↑ Morean, Meghan E.; Corbin, William R.; Treat, Teresa A. (2013). "The Subjective Effects of Alcohol Scale: Development and psychometric evaluation of a novel assessment tool for measuring subjective response to alcohol". Psychological Assessment. 25 (3): 780–795. doi:10.1037/a0032542. PMC   3822039 . PMID   23647036.
  17. ↑ Arias, Albert; Feinn, Richard; Kranzler, Henry R. (July 2006). "Association of an Asn40Asp (A118G) polymorphism in the μ-opioid receptor gene with substance dependence: A meta-analysis". Drug and Alcohol Dependence. 83 (3): 262–268. doi:10.1016/j.drugalcdep.2005.11.024. PMID   16387451.
  18. 1 2 3 Jones, Jermaine D.; Comer, Sandra D.; Kranzler, Henry R. (1 March 2015). "The Pharmacogenetics of Alcohol Use Disorder". Alcoholism: Clinical and Experimental Research. 39 (3): 391–402. doi:10.1111/acer.12643. ISSN   1530-0277. PMC   4348335 . PMID   25703505.
  19. ↑ Koob, George F.; Le Moal, Michel (1 February 2001). "Drug Addiction, Dysregulation of Reward, and Allostasis". Neuropsychopharmacology. 24 (2): 97–129. doi: 10.1016/S0893-133X(00)00195-0 . ISSN   0893-133X. PMID   11120394.
  20. ↑ C. Garbutt, James (1 June 2010). "Efficacy and Tolerability of Naltrexone in the Management of Alcohol Dependence". Current Pharmaceutical Design. 16 (19): 2091–2097. doi:10.2174/138161210791516459. PMID   20482515.
  21. ↑ King, Andrea C.; Volpicelli, Joseph R.; Frazer, A.; O'Brien, Charles P. (1997). "Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence". Psychopharmacology. 129 (1): 15–22. doi:10.1007/s002130050156. ISSN   0033-3158. PMID   9122358. S2CID   25116120.
  22. ↑ McCaul, Mary E.; Wand, Gary S.; Eissenberg, Thomas; Rohde, Charles A.; Cheskin, Lawrence J. (1 May 2000). "Naltrexone Alters Subjective and Psychomotor Responses to Alcohol in Heavy Drinking Subjects". Neuropsychopharmacology. 22 (5): 480–492. doi: 10.1016/S0893-133X(99)00147-5 . ISSN   0893-133X. PMID   10731623.
  23. ↑ Ray, Lara A.; Hutchison, Kent E. (1 September 2007). "Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response". Archives of General Psychiatry. 64 (9): 1069–77. doi: 10.1001/archpsyc.64.9.1069 . ISSN   0003-990X. PMID   17768272.
  24. ↑ Drobes, David J.; Anton, Raymond F.; Thomas, Suzanne E.; Voronin, Konstantin (1 September 2004). "Effects of Naltrexone and Nalmefene on Subjective Response to Alcohol Among Non-Treatment-Seeking Alcoholics and Social Drinkers". Alcoholism: Clinical and Experimental Research. 28 (9): 1362–1370. doi: 10.1097/01.ALC.0000139704.88862.01 . ISSN   1530-0277. PMID   15365307.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.